cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Vericel Corporation
6 own
8 watching
Current Price
$0
$-1.09
(-3.52%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,469.84M
52-Week High
52-Week High
43.9699
52-Week Low
52-Week Low
17.3
Average Volume
Average Volume
0.05M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
243.8501
iconMarket Capitalization1,469.84M
icon52-Week High43.9699
icon52-Week Low17.3
iconAverage Volume0.05M
iconDividend Yield--
iconP/E Ratio243.8501
What does the Vericel Corporation do?
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. The company also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Vericel Corporation make?
News & Events about Vericel Corporation.
Benzinga
12days ago
Latest Ratings for VCEL DateFirmActionFromTo Feb 2022SVB LeerinkMaintainsOutperform Dec 2021Truist SecuritiesMaintainsBuy Aug 2021SVB LeerinkMaintainsOutperform View More Analyst Ratings for VCEL View the Latest Analyst Ratings read more...
Globe Newswire
29days ago
Full-Year Total Revenue Expected to be Approximately $164 to $165 Million MACI Full-Year Revenue Expected to be at the High End of Guidance Range, with Fourth Quarter Revenue Growth of Approximately 24% MACI Arthroscopic Commercial Launch Now Planned for 2024 CAMBRIDGE, Mass., Jan. 10, 2023 (GLOBE ...
Globe Newswire
1month ago
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 41st Annual J.P. Morgan Healthcare Conference. The ...
Globe Newswire
3 months ago
CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health...
Globe Newswire
3 months ago
Total Net Product Revenue of $38.6 Million MACI Net Revenue Increased 30% to $31.0 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care ...
Frequently Asked Questions
Frequently Asked Questions
What is Vericel Corporation share price today?
plus_minus_icon
Can Indians buy Vericel Corporation shares?
plus_minus_icon
How can I buy Vericel Corporation shares from India?
plus_minus_icon
Can Fractional shares of Vericel Corporation be purchased?
plus_minus_icon
What are the documents required to start investing in Vericel Corporation stocks?
plus_minus_icon
What is today’s traded volume of Vericel Corporation?
plus_minus_icon
What is today’s market capitalisation of Vericel Corporation?
plus_minus_icon
What is the 52-Week High and Low Range of Vericel Corporation?
plus_minus_icon
What percentage is Vericel Corporation down from its 52-Week High?
plus_minus_icon
What percentage is Vericel Corporation up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-1.09
(-3.52%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Kura Oncology Inc
Kura Oncology Inc
$12.82
$-0.33 (-2.53 %)
Mesoblast
Mesoblast
$4.11
$0.00 (0.00 %)
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
$11.56
$-0.19 (-1.58 %)
Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc.
$10.65
$-0.61 (-5.38 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Kura Oncology Inc
Kura Oncology Inc
$12.82
$-0.33 (-2.53 %)
Mesoblast
Mesoblast
$4.11
$0.00 (0.00 %)
Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
$11.56
$-0.19 (-1.58 %)
Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc.
$10.65
$-0.61 (-5.38 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00